Therapeutic potential of carbonic anhydrase IX inhibitors in multiple myeloma
Scientific-Disciplinary Group
06/MEDS-02 - Experimental Medicine, Pathophysiology And Clinical Pathology
Description
BACKGROUND. Multiple myeloma (MM) is an incurable hematologic malignancy that develops within the hypoxic bone marrow microenvironment. Adaptation to hypoxia induces the expression of proteins involved in pH regulation, including carbonic anhydrase IX (CAIX), an enzyme associated with poor prognosis in solid tumors but still poorly investigated in MM.OBJECTIVES. (i) To define the biological role of CAIX in MM growth and progression; (ii) to evaluate the therapeutic potential of CAIX inhibitors (CAIXi) as single agents or in combination with proteasome inhibitors (PIs); and (iii) to develop hybrid CAIXi/PI molecules.METHODS. Studies will be conducted using cellular and murine models, including genetically engineered models and patient-derived samples.EXPECTED RESULTS. The project aims to validate CAIX as a novel therapeutic target and to develop innovative treatment strategies for patients with newly diagnosed and/or relapsed/refractory MM.
Job posting website
Number of positions
1
Funding body
Università degli studi di Brescia
Selection process
Click to expand
View the original posting on the MUR website: Go to MUR website